{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:06:31Z","timestamp":1772276791838,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T00:00:00Z","timestamp":1319673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> SBR759 is a calcium\u2010free, polymeric, iron(III)\u2010based oral phosphate binder, in development for the treatment of hyperphosphatemia. The efficacy and safety of SBR759 was compared with sevelamer hydrochloride in chronic kidney dialysis patients on hemodialysis.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Japanese and Taiwanese hyperphosphatemic patients who were on hemodialysis (<jats:italic>n<\/jats:italic>\u2003=\u2003203) received starting doses of 3.0 or 4.5\u2003g\/day SBR759 or 2.4 or 4.8\u2003g\/day sevelamer\u2010hydrochloride (HCl) based on baseline phosphate levels. Daily doses were up\u2010titrated every 2\u2003weeks to reach the Kidney Disease Outcomes Quality Initiative (K\/DOQI) recommended target serum phosphate concentration \u22641.7\u2003mmol\/L. The key endpoints were proportion of patients achieving target serum phosphate and the safety at week 12.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> SBR759 showed a superior phosphate response at week 12 compared with sevelamer\u2010HCl (83% <jats:italic>vs<\/jats:italic> 54% patients; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). Mean serum calcium concentrations were unaffected by either treatment. Similar incidences of adverse events and serious adverse events were seen with SBR759 and sevelamer\u2010HCl (90.3% <jats:italic>vs<\/jats:italic> 94.1% and 5.2% <jats:italic>vs<\/jats:italic> 4.4%, respectively), but overall discontinuation rates were lower with SBR759 (11.9% <jats:italic>vs<\/jats:italic> 20.6%). The proportion of patients experiencing gastrointestinal disorders was lower in SBR759 <jats:italic>versus<\/jats:italic> sevelamer\u2010HCl. No treatment\u2010related serious adverse events were reported.<\/jats:p><jats:p><jats:bold>Conclusions:\u2003<\/jats:bold> SBR759 showed superior phosphate control with a favorable tolerability profile compared to sevelamer\u2010HCl in hemodialysis patients.<\/jats:p>","DOI":"10.1111\/j.1440-1797.2011.01509.x","type":"journal-article","created":{"date-parts":[[2011,8,20]],"date-time":"2011-08-20T07:30:29Z","timestamp":1313825429000},"page":"743-750","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of SBR759, a novel calcium\u2010free, iron(III)\u2010based phosphate binder, in Asian patients undergoing hemodialysis: A 12\u2010week, randomized, open\u2010label, dose\u2010titration study <i>versus<\/i> sevelamer hydrochloride"],"prefix":"10.1111","volume":"16","author":[{"given":"JIN\u2010BOR","family":"CHEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHOU\u2010SHAN","family":"CHIANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUNG\u2010CHUN","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SEIICHI","family":"OBAYASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAKI","family":"NAGASAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J MARK","family":"HEXHAM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ALISON","family":"BALFOUR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GUIDO","family":"JUNGE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKASHI","family":"AKIBA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAFUMI","family":"FUKAGAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.7.1014"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912522"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.08.009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-6686.2009.00052.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05880809"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm421"},{"issue":"5","key":"e_1_2_6_9_2","first-page":"887","article-title":"Phosphate binding therapy in dialysis patients: Focus on lanthanum carbonate","volume":"4","author":"Mohammed IA","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000313492"},{"issue":"3","key":"e_1_2_6_11_2","first-page":"286","article-title":"Lanthanum carbonate treatment, for up to 6\u2003years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis","volume":"71","author":"Hutchison AJ","year":"2009","journal-title":"Clin. Nephrol."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.23"},{"issue":"3","key":"e_1_2_6_13_2","first-page":"739","article-title":"K\/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: Can we achieve them?","volume":"38","author":"Wei M","year":"2006","journal-title":"Int. Urol. Nephrol."},{"key":"e_1_2_6_14_2","unstructured":"Renagal tablets (sevelamer hydrochloride) 400 & 800\u2003mg: Highlights of prescribing information. [Cited 13 Apr 2010.] Available from URL:http:\/\/www.genzymeclinicalresearch.com\/pdf\/renagel_pi.pdf"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP62104"},{"key":"e_1_2_6_16_2","unstructured":"K\/DOQI National Kidney Foundation: Clinical Practice Guidelines for Hemodialysis Adequacy.2000. Update 2000; Guideline 6: Target Iron Level. [Cited 13 April 2010.] Available from URL:http:\/\/wwwkidneyorg\/PROFESSIONALS\/kdoqi\/guidelines_updates\/doqi_uptochtml"},{"issue":"2","key":"e_1_2_6_17_2","first-page":"383","article-title":"Effects of PB\u201094 (Sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients \u2013 A randomized, open label, dose titration study of PB\u201004 versus Caltan Tab. 500 (calcium carbonate)","volume":"55","author":"Suzuki M","year":"2003","journal-title":"Kidney Dial."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.63.s85.17.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050622"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.340"},{"key":"e_1_2_6_21_2","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2010MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2010Mineral and Bone Disorder (CKD\u2010MBD)","volume":"113","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease","volume":"42","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00215.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP68386"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1797.2011.01509.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1797.2011.01509.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:37:59Z","timestamp":1697254679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1797.2011.01509.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1111\/j.1440-1797.2011.01509.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1797.2011.01509.x","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]},"assertion":[{"value":"2011-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}